Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 19/20 | 0.46 |
| ▸ | PPARD | Q03181 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4756730 | 1.00 | FFAR1 (0.46) | FFAR1PPARDPPARG | |
| SCHEMBL5530898 | 1.00 | FFAR1 (0.46) | FFAR1PPARDPPARG | |
| SCHEMBL14378496 | 0.90 | FFAR1 (0.46) | FFAR1PPARDPPARG | |
| SCHEMBL14378621 | 0.90 | FFAR1 (0.46) | FFAR1PPARDPPARG | |
| SCHEMBL14378624 | 0.89 | FFAR1 (0.45) | FFAR1PPARDPPARG | |
| SCHEMBL14402122 | 0.89 | FFAR1 (0.42) | FFAR1PPARDPPARG | |
| SCHEMBL14378501 | 0.83 | FFAR1 (0.53) | FFAR1PPARDPPARG | |
| SCHEMBL14378620 | 0.83 | FFAR1 (0.53) | FFAR1PPARDPPARG | |
| SCHEMBL14378495 | 0.82 | FFAR1 (0.40) | FFAR1PPARDPPARG | |
| SCHEMBL14378592 | 0.78 | PPARD (0.66) | FFAR1PPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001844-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | FFAR1 326/4885PPARD 243/4885PPARG 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.